While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...
Research reveals men skipping prostate cancer screenings are 45% more likely to die from the disease. Evidence from a large European study indicates P ...
PET/CT scans using an experimental prostate-specific membrane antigen (PSMA) imaging agent can identify SC nodal metastasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback